DIAMYD MEDICAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.9 SEK | +5.68% |
|
+22.43% | +81.13% |
| Apr. 18 | Diamyd Medical Raises SEK57 Million in Rights Issue | MT |
| Apr. 12 | Recruitment Milestone Reaches in Diamyd® Phase 3 Trial | CI |
Valuation
| Fiscal Period: August | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 577.6 | 2,736 | 2,412 | 1,122 | 839.8 | 1,221 | - | - |
| Enterprise Value (EV) 1 | 520.9 | 2,667 | 2,273 | 1,002 | 712.3 | 1,082 | 1,191 | 1,187 |
| P/E ratio | -16.7 x | 396 x | 37.4 x | -10.4 x | -7.53 x | -8.95 x | -7.21 x | -5.89 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 353 x | 2,432 x | 9,533 x | 2,470 x | 42.8 x | 407 x | 407 x | 407 x |
| EV / Revenue | 318 x | 2,371 x | 8,982 x | 2,207 x | 36.3 x | 361 x | 397 x | 396 x |
| EV / EBITDA | -14.3 x | 270 x | -26.7 x | -8.91 x | -7.12 x | -8.2 x | -7.35 x | -6.03 x |
| EV / FCF | -13.3 x | 188 x | -20 x | -8.87 x | -6.69 x | -7.9 x | -7.44 x | -6.06 x |
| FCF Yield | -7.52% | 0.53% | -5% | -11.3% | -15% | -12.7% | -13.4% | -16.5% |
| Price to Book | 9.28 x | 39.6 x | 13 x | 5.21 x | 4.45 x | 6.69 x | 18.9 x | 19.5 x |
| Nbr of stocks (in thousands) | 69,170 | 69,170 | 71,570 | 76,927 | 85,782 | 102,619 | - | - |
| Reference price 2 | 8.350 | 39.55 | 33.70 | 14.58 | 9.790 | 11.90 | 11.90 | 11.90 |
| Announcement Date | 10/2/19 | 10/7/20 | 10/13/21 | 10/5/22 | 10/11/23 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: August | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.637 | 1.125 | 0.253 | 0.454 | 19.61 | 3 | 3 | 3 |
| EBITDA 1 | -36.43 | 9.888 | -85.1 | -112.4 | -100.1 | -132 | -162 | -197 |
| EBIT 1 | -36.57 | 9.739 | -85.88 | -114.9 | -104.9 | -134 | -166 | -202 |
| Operating Margin | -2,233.9% | 865.69% | -33,944.66% | -25,316.52% | -535.08% | -4,466.67% | -5,533.33% | -6,733.33% |
| Earnings before Tax (EBT) 1 | -36.61 | 9.709 | 60.05 | -103.5 | -100.2 | -133 | -165 | -201 |
| Net income 1 | -36.61 | 9.709 | 60.05 | -103.5 | -100.2 | -133 | -165 | -201 |
| Net margin | -2,236.41% | 863.02% | 23,733.6% | -22,801.1% | -510.95% | -4,433.33% | -5,500% | -6,700% |
| EPS 2 | -0.5000 | 0.1000 | 0.9000 | -1.400 | -1.300 | -1.330 | -1.650 | -2.020 |
| Free Cash Flow 1 | -39.18 | 14.18 | -113.7 | -113 | -106.5 | -137 | -160 | -196 |
| FCF margin | -2,393.71% | 1,260% | -44,937.94% | -24,891.41% | -543.23% | -4,566.67% | -5,333.33% | -6,533.33% |
| FCF Conversion (EBITDA) | - | 143.36% | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 146% | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 10/2/19 | 10/7/20 | 10/13/21 | 10/5/22 | 10/11/23 | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: August | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 56.7 | 68.4 | 139 | 120 | 128 | 139 | 30 | 34 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -39.2 | 14.2 | -114 | -113 | -107 | -137 | -160 | -196 |
| ROE (net income / shareholders' equity) | -69.2% | 14.4% | 45.9% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.9000 | 1.000 | 2.600 | 2.800 | 2.200 | 1.780 | 0.6300 | 0.6100 |
| Cash Flow per Share | -0.6000 | - | - | - | - | - | - | - |
| Capex 1 | - | 1.98 | - | - | 11.4 | 7 | - | - |
| Capex / Sales | - | 175.91% | - | - | 58.34% | 233.33% | - | - |
| Announcement Date | 10/2/19 | 10/7/20 | 10/13/21 | 10/5/22 | 10/11/23 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +81.13% | 111M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- DMYD B Stock
- Financials Diamyd Medical AB
